← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
76	76 Coya Therapeutics COYA $99.7M	–	–	–	–
77	77 Caribou Biosciences CRBU $50.4M	–	–	–	–
78	78 DELISTED CARGO Therapeutics CRGX	–	–	–	–
79	79 CRISPR Therapeutics CRSP $4.76B	–	–	–	–
80	80 DELISTED CATALENT, INC. CTLT	–	–	–	–
81	CYAD 81 DELISTED Celyad Oncology SA American Depositary Shares CYAD	–	–	–	–
82	DBTX 82 DELISTED Decibel Therapeutics, Inc. Common Stock DBTX	–	–	–	–
83	83 DELISTED DermTech, Inc. Common Stock DMTK	–	–	–	–
84	84 Ginkgo Bioworks DNA $692M	–	–	–	–
85	85 Design Therapeutics DSGN $645M	–	–	–	–
86	86 Precision BioSciences DTIL $159M	–	–	–	–
87	87 Editas Medicine EDIT $361M	–	–	–	–
88	88 enGene Therapeutics ENGN $112M	–	–	–	–
89	89 Enlivex Ltd ENLV $4.08M	–	–	–	–
90	90 Estrella Immunopharma ESLA $18.7M	–	–	–	–
91	91 Fate Therapeutics FATE $214M	–	–	–	–
92	92 FibroBiologics FBLG $6.88M	–	–	–	–
93	93 4D Molecular Therapeutics FDMT $671M	–	–	–	–
94	94 Fulgent Genetics FLGT $545M	–	–	–	–
95	FRLN 95 DELISTED Freeline Therapeutics Holdings plc American Depositary Shares FRLN	–	–	–	–
96	96 DELISTED Generation Bio GBIO	–	–	–	–
97	97 CytoMed Therapeutics GDTC $10.5M	–	–	–	–
98	98 Guardant Health GH $21.3B	–	–	–	–
99	GMDA 99 DELISTED Gamida Cell Ltd. Ordinary Shares GMDA	–	–	–	–
100	100 Corgi Genomics & Precision Medicine ETF GNMX $1.6M	–	–	–	–